Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1686-1692

  Sadler, Brian M ^a   Hanson, Cynthia D ^a   Chittick, Gregory E ^a   Symonds, William T ^a   Roskell, Neil S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GELATIN; PLACEBO; PROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPESTHESIA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032779413     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1686     Document Type: Article

References (22)

1. Barry, M., S. Gibbons, D. Back, and F. Mulcahy. 1997. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32:194-209.
2. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsend, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1998. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 280:78-86.
3. Centers for Disease Control and Prevention. 1998. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morbid. Mortal. Weekly Rep. 47(RR 5):43-82.
4. Centers for Disease Control and Prevention. 1997. Update: trends in AIDS incidence - United States, 1996. Morbid. Mortal. Weekly Rep. 46:861-864.
5. Conover, J. W. 1980. Some methods based on ranks, p. 213-343. In Practical nonparametric statistics, 2nd ed. John Wiley & Sons, Inc., New York, N.Y.
6. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors: a review for clinicians. JAMA 277:145-153.
7. Flexner, C. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338:1281-1291.
8. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker Inc., New York, N.Y.
9. 8a. Glaxo Wellcome Inc. Data on file. Glaxo Wellcome Inc., Research Triangle Park, N.C.
10. Kakuda, T. N., K. A. Struble, and S. C. Piscitelli. 1998. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am. J. Health-Syst. Pharm. 55:233-254.
11. Kim, E. E., C. T. Baker, M. D. Dwyer, M. A. Mureko, B. G. Rao, R. D. Tung, and M. A. Navia. 1995. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1181-1182.
12. Livingston, D. J., S. Pazhanisamy, D. J. T. Porter, J. A. Partaledis, R. D. Tung, and G. R. Painter. 1995. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245.
13. Medical Economics Co. 1998. Physician's desk reference, vol. 52, p. 459-464. Medical Economics Co., Montvale, N.J.
14. Painter, G. R., M. H. St Clair, P. DeMiranda, D. Reynolds, S. Ching, R. Dornsife, D. J. Livingston, S. Pazhanisamy, and R. Tang. 1995. An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94), abstr. LB5. In Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections.
15. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
16. Quart, B. D., S. K. Chapman, J. Peterkin, S. Webber, and S. Oliver. 1995. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343, abstr. LB3. In Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections.
17. Sadler, B. M., M. Elkins, C. Hanson, J. Rooney, J. Millard, M. R. Blum, and G. Painter. 1995. The safety and pharmacokinetics of 141W94: an HIV protease inhibitor, abstr. 564, p. 90. In Program and abstracts of the 5th European Conference on Clinical Aspects and Treatment of HIV Infection.
18. Shaw, T. M., P. E. O. Williams, G. J. Nuirhead, S. Harris, N. Watson, and W. Nimmo. 1993. Effect of timing of food and gastric pH on exposure to Ro31-8959, HIV proteinase inhibitor in healthy subjects, abstr. PO-B30-2199, p. 502. In Abstracts of the IXth International Conference on AIDS.
19. St Clair, M., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. Sadler, M. R. Blum, and G. Painter. 1996. In vitro activity of 141W94 (VX-478) in combination with other antiviral agents. Antivir. Res. 29:53-56.
20. Symonds, W. T., B. M. Sadler, G. E. Chittick, and J. Moss. 1996. A clinical study of the HIV-1 protease inhibitor, 141W94 (VX-478) to evaluate a new soft gelatin capsule formulation and to determine the effects of food upon bioavailability. Antivir. Res. 30:A42.
21. Woolley, J., S. Studenberg, C. Boehlert, G. Bowers, A. Sinhababu, and P. Adams. 1997. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94, abstr. A-60, p. 12. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Yeh, K. C., P. J. Deutsch, H. Haddix, M. Hesney, V. Hoagland, W. D. Ju, S. J. Justice, B. Osborne, A. T. Sterrett, J. A. Stone, E. Woolf, and S. Waldman. 1998. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother. 42:332-338.